Sun Pharmaceutical acquires Innovcare Lifesciences

M&A / JV 20 Jun 2026 · Announced· ✓ Verified

Sun Pharmaceutical Industries Limited, a Mumbai-listed multinational pharmaceutical manufacturer (BSE: 500470, NSE: SUNPHARMAIND), announced the acquisition of Innovcare Lifesciences Private Limited via a mandatory NSE CORPFACTS general update filing dated 20 June 2026. No consideration amount, funding structure, closing conditions, or material acquisition agreement terms have been publicly disclosed. The transaction is believed to target portfolio consolidation in specialty segments, potentially including dermatology or gastroenterology therapeutic areas. The deal status is announced but not yet reported as closed.

Why it mattersThe undisclosed valuation structure and lack of public pricing suggests this was a strategic bolt-on acquisition below material threshold or negotiated as a private transaction without equity/debt financing triggers requiring disclosure-routine practice for pharma tuck-ins under ₹300–500 cr.
Counsel—
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals